Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors
暂无分享,去创建一个
D. Campanacci | L. Livi | M. Sottili | I. Desideri | M. Loi | C. Becherini | P. Bonomo | G. Beltrami | M. Mangoni | I. Meattini | D. Greto | S. Scoccianti | L. Dominici | G. Salvatore | P. Garlatti | Angela Silvano | Chiara Gerini | C. D. Paoli | A. Silvano
[1] B. Pasini,et al. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models , 2017, Molecular Cancer.
[2] C. Lucchesi,et al. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas , 2017, Journal of Hematology & Oncology.
[3] C. Pratilas,et al. Targeted therapy for soft tissue sarcomas in adolescents and young adults , 2017, Adolescent health, medicine and therapeutics.
[4] L. Livi,et al. A PPAR-gamma agonist protects from radiation-induced intestinal toxicity , 2017, United European gastroenterology journal.
[5] M. Khasraw,et al. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? , 2017, Clinical and Translational Oncology.
[6] R. Mairs,et al. Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells , 2017, International journal of radiation biology.
[7] I. Judson,et al. UK guidelines for the management of soft tissue sarcomas , 2016, Clinical Sarcoma Research.
[8] T. Galloway,et al. The Role for Radiation Therapy in the Management of Sarcoma. , 2016, The Surgical clinics of North America.
[9] L. Povirk,et al. Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition , 2016, Radiation Research.
[10] Iain J Hyndman,et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma , 2016, BMC Cancer.
[11] Z. Cui,et al. Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells , 2016, Oncology research.
[12] T. Kondo,et al. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor , 2016, Genes to cells : devoted to molecular & cellular mechanisms.
[13] D. Vanel,et al. Translational research in diagnosis and management of soft tissue tumours , 2016, Cancer Imaging.
[14] C. Ciccarelli,et al. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population , 2016, Molecular Cancer.
[15] F. Engert,et al. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway , 2015, Molecular Cancer Therapeutics.
[16] M. O’Connor,et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] T. Stokke,et al. Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation , 2015, Cell cycle.
[18] J. Mora,et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2015, Oncotarget.
[19] C. Scott,et al. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Jong-Soo Lee,et al. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer , 2015, BMC Cancer.
[21] E. Deeks. Olaparib: First Global Approval , 2015, Drugs.
[22] G. Demetri,et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy , 2014, BMC Cancer.
[23] E. Yang,et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. , 2014, Gynecologic oncology.
[24] B. Telfer,et al. Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft , 2011, Molecular Cancer Therapeutics.
[25] F. Chibon,et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics , 2011, The Journal of pathology.
[26] R. Bristow,et al. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. , 2010, Seminars in radiation oncology.
[27] A. Chalmers,et al. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. , 2008, International journal of radiation oncology, biology, physics.
[28] P. Metrakos,et al. Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer , 2008, Pharmacological Reviews.
[29] Linda J. Kuo,et al. γ-H2AX - A Novel Biomarker for DNA Double-strand Breaks , 2008 .
[30] M. Cohen-Armon. PARP-1 activation in the ERK signaling pathway. , 2007, Trends in pharmacological sciences.
[31] Stephen L. Abrams,et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.
[32] David H. Johnson,et al. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models , 2007, Clinical Cancer Research.
[33] G. de Murcia,et al. The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[34] S. Jackson,et al. Sensing and repairing DNA double-strand breaks. , 2002, Carcinogenesis.
[35] Lewis C Cantley,et al. PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.
[36] D. Ward,et al. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Piccart,et al. An update on PARP inhibitors—moving to the adjuvant setting , 2015, Nature Reviews Clinical Oncology.